Other

NAD+

Limited human data

A coenzyme, not a peptide.

SubQIMIntermediateNot approved anywherelongevityfocus and cognitionmetabolic healthrecovery and sleep

Also known as Nicotinamide adenine dinucleotide · NAD

At a glance

Dose summary

Typical dose100 mg
Range25 mg–250 mg
Frequency3×/week
Half-lifeUnknown
ScheduleThree times a week
Cycle length4 weeks
RouteSubQ · IM
Experience levelIntermediate
Evidence gradeLimited human data
ApprovalNot approved anywhere
Where the dose comes fromCommunity practice, not a trial

No reliable human half-life has been published for NAD+, so none is listed rather than guessed at.

No regulator and no trial set these numbers. They describe what people actually do, recorded so you can see the range rather than guess at it — which is not the same thing as a recommendation.

Reconstitution

What to draw, at the usual vial

A 500 mg vial reconstituted with 5 mL of bacteriostatic water gives 100.00 mg/mL. A typical 100 mg dose is 1.000 mL — pull the plunger to 100 units on a U-100 syringe.

Concentration100.00 mg/mL
Draw volume1.000 mL
U-100 units100 units
Doses per vial5

Same dose, other vial sizes

VialWaterConcentrationDrawUnitsDoses
100 mg5 mL20.00 mg/mL5.000 mL500 units1
500 mg5 mL100.00 mg/mL1.000 mL100 units5
750 mg5 mL150.00 mg/mL0.667 mL66.7 units7
1000 mg5 mL200.00 mg/mL0.500 mL50 units10

The highlighted row is the one quoted above: the smallest listed vial that holds at least four typical doses. Change any of it — a different vial, more or less water, a different dose — on the reconstitution calculator, which draws the syringe to true U-100 graduations.

Mechanism & evidence

What it is, and what is known

A coenzyme, not a peptide. Human evidence for injected NAD+ itself is weak: most controlled trials study oral precursors (nicotinamide riboside, NMN) rather than parenteral NAD+, and the anti-ageing claims attached to it outrun the data. Doses here are large — the range is 25-250 mg with 100 mg typical, so the microgram figures are in the tens and hundreds of thousands (100 mg = 100,000 mcg). NAD+ is also very commonly given intravenously at 250-1000 mg per infusion over 1-4 hours; there is no IV route in this dataset, so subq is listed and IV is noted here instead.

IV dosing is not interchangeable with the subq figures above. Subcutaneous administration is notoriously stinging; users typically start at the low end, inject slowly, and dose every other day rather than daily. Circulating NAD+ is cleared and metabolised rapidly, so no meaningful half-life is listed.

The caveat

Most controlled trials study oral precursors, not injected NAD+. The anti-ageing claims outrun the data.

Tolerability

Reported side effects

  • Marked burning or stinging at the injection site, the most common complaint
  • Flushing, chest tightness or nausea if given too quickly
  • Cramping and a wave of anxiety or restlessness during administration
  • Headache
  • Fatigue for a few hours afterwards

Hard stops

Do not use this if

  • Pregnancy, possible pregnancy, or breastfeeding
  • Under 18

These are flags, not a screening. They do not replace a conversation with a clinician who knows your history.

Handling

Storage

Sealed powder, refrigerated24 months
After reconstitution, refrigerated30 days

Keep it cold, keep it dark, and label the vial with the date you mixed it. Discard anything cloudy or past the window above.

Combinations

Commonly stacked with

Stacking multiplies the side-effect surface and makes it impossible to tell which compound did what. Add one thing at a time.

Where it shows up

Protocols using this compound

References

Sources

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.